39 results on '"Nichetti, F."'
Search Results
2. Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation
3. 56P Multi-omic profiling in cholangiocarcinoma to enable scientific advancement within the DKFZ/NCT/DKTK MASTER study
4. 124P Clinicopathological nomogram for predicting fibroblast growth factor receptor 2 (FGFR2) gene fusion/rearrangement (F/R) in intrahepatic cholangiocarcinoma (iCCA)
5. SO-3 Clinical relevance and actionability of BRAF alterations in advanced biliary tract cancer: Preliminary results from the multicenter B-REAL study
6. P-275 FOLFOX versus FOLFIRI as second-line treatment after cisplatin-gemcitabine in patients with advanced biliary tract cancers
7. P-167 Type 2 diabetes as a predictive and prognostic factor in advanced pancreatic cancer: Preliminary results of the Italian, observational PANCAKE study
8. P-169 Early-onset biliary tract cancer: An overview of clinical presentation, risk factors, molecular profile and outcome in a multicentric Italian cohort
9. PD-26 Efficacy of PD-1 blockade in patients with dMMR/MSI-H metastatic colorectal versus gastric cancers: A large, multicenter, cohort study
10. PD-17 Multicentric prospective study assessing clinical benefit of targeted treatment for patients with biliary tract cancers
11. 1312P Chemotherapy followed by immunotherapy compared to reverse sequence in NSCLC with PD-L1 low expression: PFS2 analysis
12. 337P Efficacy of everolimus plus exemestane in CDK 4/6 inhibitors-pretreated or naïve HR-positive/HER2-negative breast cancer patients: A secondary analysis of the EVERMET study
13. 339P Impact of blood glucose levels on the efficacy of everolimus-exemestane in patients with advanced HR-positive/HER2 negative breast cancer: The EVERMET study
14. 1702P COVID-19 risk for patients undergoing anticancer treatment at the outpatient clinic of the National Cancer Institute of Milan: The COVINT study
15. 66P Preoperative predictors of long-term outcomes for resectable intrahepatic cholangiocarcinoma (iCCA): Is there a space for neoadjuvant?
16. 146P Safety and metabolic effects of fasting-mimicking diet in breast cancer patients
17. 32P The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of CDK 4/6 inhibitors in women with hormone receptor-positive/HER2-negative advanced breast cancer
18. Is MGMT methylation a new therapeutic target for biliary tract cancer?
19. MGMT methylation in metastatic pancreatic cancer (mPAC): A single center experience
20. The role of modulation of somatostatin analogues (SSAs) in association to peptide receptor radionuclide therapy (PRRT) after SSAs progression disease (PD) in advanced well-differentiated (WD) entero-pancreatic neuroendocrine tumours (EP-NETs)
21. Analysis of circulating biomarkers in a randomized phase II trial of maintenance oral metronomic vinorelbine in advanced NSCLC following platinum-based chemotherapy: A correlative MA.NI.LA. trial study
22. Combination of brain radiotherapy (RT) and immunotherapy (IT) in a single Institution cohort of patients (pts) with metastatic melanoma (MM)
23. Estimation of 12-weeks life expectancy in patients (pts) with metastatic gastric cancer (mGC) candidated for second-line treatment: the “Gastric Life” nomogram
24. Brain radiotherapy (RT) and immunotherapy (IT) for metastatic melanoma (MM): a retrospective single institution experience
25. Pro-GRP in small cell lung cancer
26. 732P - Is MGMT methylation a new therapeutic target for biliary tract cancer?
27. 712P - MGMT methylation in metastatic pancreatic cancer (mPAC): A single center experience
28. Pharmacogenomic evaluation of single nucleotide polymorphisms associated with oxaliplatin-induced peripheral neuropathy: a preliminary study
29. Pro-gastrin releasing peptide (pro-GRP) in small cell lung cancer staging
30. 1324P - The role of modulation of somatostatin analogues (SSAs) in association to peptide receptor radionuclide therapy (PRRT) after SSAs progression disease (PD) in advanced well-differentiated (WD) entero-pancreatic neuroendocrine tumours (EP-NETs)
31. 139P - Analysis of circulating biomarkers in a randomized phase II trial of maintenance oral metronomic vinorelbine in advanced NSCLC following platinum-based chemotherapy: A correlative MA.NI.LA. trial study
32. Risk of thromboembolic events (TEE) in metastatic colorectal cancer (mCRC) patients with single nucleotide polymorphisms (SNPs) in Factor V Leiden (FVL), Prothrombin, Plasminogen Activator Inhibitor-1 (PAI-1) and Methylenetetrahydrofolate Reductase (MTHFR)
33. 27P - Combination of brain radiotherapy (RT) and immunotherapy (IT) in a single Institution cohort of patients (pts) with metastatic melanoma (MM)
34. G3 - Brain radiotherapy (RT) and immunotherapy (IT) for metastatic melanoma (MM): a retrospective single institution experience
35. D9 - Estimation of 12-weeks life expectancy in patients (pts) with metastatic gastric cancer (mGC) candidated for second-line treatment: the “Gastric Life” nomogram
36. 56P - Pro-GRP in small cell lung cancer
37. D23 - Pharmacogenomic evaluation of single nucleotide polymorphisms associated with oxaliplatin-induced peripheral neuropathy: a preliminary study
38. A34 - Pro-gastrin releasing peptide (pro-GRP) in small cell lung cancer staging
39. E16 - Risk of thromboembolic events (TEE) in metastatic colorectal cancer (mCRC) patients with single nucleotide polymorphisms (SNPs) in Factor V Leiden (FVL), Prothrombin, Plasminogen Activator Inhibitor-1 (PAI-1) and Methylenetetrahydrofolate Reductase (MTHFR)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.